Literature DB >> 1544831

The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.

M I Walton1, N Sugget, P Workman.   

Abstract

DT-diaphorase is a unique two electron (2e) donating reductase catalyzing either bioactivation or bioprotection reactions. Using human and rodent DT-diaphorase preparations (cell extracts and purified enzyme) we have characterized the reductive metabolism of the hypoxic cell cytotoxins EO9, mitomycin C (MMC), CB 1954, and SR 4233 in vitro. Drug metabolism was assayed spectrophotometrically or by HPLC, with dicoumarol as a selective inhibitor. DNA damage was measured using an agarose gel mobility technique with plasmid pBR322 DNA. The developmental indoloquinone, EO9, was metabolized by both rat Walker and human HT29 tumor DT-diaphorases. Reduction proceeded 5-fold more efficiently with the rat than the human tumor enzyme and resulted in single-strand breaks in plasmid DNA. The structurally related MMC was metabolized much more slowly than EO9 by the rat Walker tumor enzyme and there was no detectable reaction with the human HT29 tumor DT-diaphorase. No DNA damage was seen with MMC for either enzyme. The dinitrophenylaziridine CB 1954 was reduced by both human and rat enzymes forming, preferentially, the highly toxic 4-hydroxylamine as a 4e reduction product. Rates were 3-fold lower than for the human tumor enzyme. SR 4233 was also reduced by the rat tumor enzyme predominantly via 4e reduction to the benzotriazine SR 4330, in a novel reaction mechanism. This appears to be a bioprotection pathway that bypasses the toxic 1e radical formed by other reductases. Such information may be valuable in the selection of hypoxic cell cytoxins to treat human tumors high or low in DT-diaphorase and should facilitate 'enzyme-directed' analogue development.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544831     DOI: 10.1016/0360-3016(92)90495-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Authors:  Bryan T Oronsky; Susan J Knox; Jan Scicinski
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

2.  Oncogenic potential of bifunctional bioreductive drugs.

Authors:  T K Hei; S X Liu; E J Hall
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 3.  Significance of Specific Oxidoreductases in the Design of Hypoxia-Activated Prodrugs and Fluorescent Turn off-on Probes for Hypoxia Imaging.

Authors:  Ewelina Janczy-Cempa; Olga Mazuryk; Agnieszka Kania; Małgorzata Brindell
Journal:  Cancers (Basel)       Date:  2022-05-29       Impact factor: 6.575

Review 4.  DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Authors:  D Ross; D Siegel; H Beall; A S Prakash; R T Mulcahy; N W Gibson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

5.  Transfection of COS-1 cells with DT-diaphorase cDNA: role of a base change at position 609.

Authors:  V Misra; H J Klamut; A M Rauth
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

Review 6.  The experimental development of bioreductive drugs and their role in cancer therapy.

Authors:  P Workman; I J Stratford
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

7.  DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?

Authors:  E Smitskamp-Wilms; G Giaccone; H M Pinedo; B F van der Laan; G J Peters
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

8.  CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.

Authors:  J H Beijnen; K P Flora; G W Halbert; R E Henrar; J A Slack
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

9.  Establishment and characterization of non-small cell lung cancer cell lines resistant to mitomycin C under aerobic conditions.

Authors:  K Shibata; K Kasahara; T Bando; Y Nakatsumi; M Fujimura; T Tsuruo; T Matsuda
Journal:  Jpn J Cancer Res       Date:  1995-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.